Physician
Oncology
Dr. Carol A. Westbrook, MD
|
|
Give Review
Carol Westbrook is an expert in the field of Oncology. She went to medical school at University of Chicago Pritzker School of Medicine. University of Chicago Pritzker School of Medicine has a rank of 10 in research and a 19 in primary care She received awards:"CMS Meaningful Use Stage 1 Certification". Carol A. Westbrook is a published physician as well. She has 29 publications published. The latest was: Use of a CEPH meiotic breakpoint panel to refine the locus of limb-girdle muscular dystrophy type 1A (LGMD1A) to a 2-Mb interval on 5q31. Carol Westbrook is registered with Medicare.
Publications
- Membrane-associated and secreted genes in breast Cancer.
- Lineage specific treatment of adult patients with Acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukem...
- Novel transcription factors in human CD34 antigen-positive hematopoietic cells.
- A novel nuclear protein, 5qNCA (LOC51780) is a candidate for the myeloid Leukemia tumor suppressor gene on chromosome 5 band q31.
- Highly abundant genes in the transcriptosome of human and baboon CD34 antigen-positive bone marrow cells.
- Human mortalin (HSPA9): a candidate for the myeloid Leukemia tumor suppressor gene on 5q31.
- Cytogenetic and molecular diagnosis of chromosome 5 deletions in myelodysplasia.
- Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid Disorders on 5q31.
- High-resolution physical map and transcript identification of a prostate Cancer deletion interval on 8p22.
- A radiation hybrid breakpoint map of the Acute myeloid leukemia (AML) and limb-girdle muscular dystrophy 1A (LGMD1A) regions of chromosome 5q31 localizing 122 expresse...
- Use of a CEPH meiotic breakpoint panel to refine the locus of limb-girdle muscular dystrophy type 1A (LGMD1A) to a 2-Mb interval on 5q31.
- Modification of bacterial artificial chromosome clones using Cre recombinase: introDuction of selectable markers for expression in eukaryotic cells.
- The Smad5 gene is involved in the intracellular signaling pathways that mediate the inhibitory effects of transforming growth factor-beta on human hematopoiesis.
- Localization of the candidate tumor suppressor gene ING1 to human chromosome 13q34.
- Molecular subsets and prognostic factors in Acute lymphoblastic leukemia.
- Value of molecular monitoring during the treatment of chronic myeloid Leukemia: a Cancer and Leukemia Group B study.
- Polymerase chain reaction-based diagnosis of del (5q) in Acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval.
- Detection of MLL gene rearrangements in adult Acute lymphoblastic leukemia. A Cancer and Leukemia Group B study.
- Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases.
- Clinical significance of the BCR-ABL fusion gene in adult Acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762).
- N-ras 61 oncogene mutations in Hürthle cell Tumors.
- Analytical approaches to detection and characterization of disease-linked chromosome aberrations.
- Detection of the Philadelphia chromosome in Acute lymphoblastic leukemia by pulsed-field gel electrophoresis.
- Unexpected heterogeneity of BCR-ABL fusion mRNA detected by polymerase chain reaction in Philadelphia chromosome-positive Acute lymphoblastic leukemia.
- A phase I-II study of bialkylator chemotherapy, high-dose thiotepa, and cyclophosphamide with autologous bone marrow reinfusion in patients with advanced Cancer.
- Evidence favoring lineage fidelity in Acute nonlymphocytic leukemia: absence of immunoglobulin gene rearrangements in FAB types M4 and M5.
- Evidence for the involvement of GM-CSF and FMS in the deletion (5q) in myeloid Disorders.
- Assignment of the GM-CSF, CSF-1, and FMS genes to human chromosome 5 provides evidence for linkage of a family of genes regulating hematopoiesis and for their involvem...
Schools
U Of Chgo Div Of Bio Sci Pritzker Sch Of Med
Unic Of Los Angeles Ca
University of Chicago
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Chicago -
UCLA Medical Center -
University of Chicago Pritzker School of Medicine
Drug Facts
| NPI NUMBER | 1427130616 | |
| NPPES Provider LastName | WESTBROOK | |
| NPPES Provider FirstName | CAROL | |
| NPPES Provider ZIPCode | 187110027 | |
| NPPES Provider State | PA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 468.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 72.0 | |
| Percent Opioid Claims | 15.38 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1427130616 |
| Last Name Of The Provider | WESTBROOK |
| First Name Of The Provider | CAROL |
| View All |
Similar Doctors
|
|
Dr. Arthur N. Meyer, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paula Ronjon, MD
This Doctor is OpenDoctor Recommended.
|